The present disclosure relates generally to covers, receptacles, shrouds, couplers, constrainers and the like (collectively, sockets) for implantable medical devices, and more specifically sockets configured to enhance inter-component and/or inter-environment interactions of an implantable device.
Implantable device components are implemented in a variety of contexts, such as transcatheter mitral chordal repair devices. Improvements in the interactions between a plurality of device components in vivo, as well as interactions between the plurality of device components and the bodily environment remain to be realized.
Various examples relate to an implantable medical device (e.g., a transcatheter mitral chordal device) that includes a first component (e.g., an anchor component) and a second component coupled to the first component (e.g., a tether component). Interactions (e.g., relative movement, flexing, abrading, or other mechanical interactions) between the first and second components may benefit from being controlled (e.g., minimized) and interactions between the first and/or second components and the bodily environment may be enhanced (e.g., by encouraging tissue ingrowth and/or minimizing thrombosis). In further examples, interactions between the first and/or second components and a third component (e.g., a tether lock component) are improved (e.g., by reducing relative movement and/or facilitating inter-component docking), and interactions between the third component and the bodily environment are improved (e.g., by encouraging tissue ingrowth and/or minimizing thrombosis). Various examples provided herein relate to covers, receptacles, shrouds, couplers, constrainers, retaining members and the like (collectively referred to herein as, “sockets”) for enhancing such inter-component and inter-environment interactions of an implantable device.
According to a first example, (“Example 1”), an implantable device includes a first component; a second component flexibly coupled to the first component; and a socket extending over the first component and the second component, the socket being configured to enhance the inter-component interaction between the first and second components of the implantable device by reducing relative movement between the first and second components, wherein the socket includes one or more outer exposed surface(s) configured to exhibit one or more tiers of foreign body responses within a range of possible foreign body responses.
According to another example, (“Example 2”), further to Example 1, the one or more outer exposed surfaces is configured to exhibit a foreign body response including extracellular matrix integration.
According to another example, (“Example 3”), further to any preceding Example, the socket includes one or more layers of material that is impermeable to cellular integration.
According to another example, (“Example 4”), further to any preceding Example, the socket includes one or more layers of material having a microstructure that is oriented to provide longitudinal strength to one or more portions of the socket.
According to another example, (“Example 5”), further to any preceding Example, the socket includes one or more layers of material having a microstructure that is oriented to provide circumferential strength to one or more portions of the socket.
According to another example, (“Example 6”), further to any preceding Example, the socket includes one or more reinforcing rings.
According to another example, (“Example 7”), further to Example 6 at least one of the one or more reinforcing rings is elastically deformable to an enlarged diameter from which the one or more reinforcing rings elastically recovers.
According to another example, (“Example 8”), further to Examples 6 or 7, the one or more reinforcing rings defines a continuous, helical undulating pattern.
According to another example, (“Example 9”), further to any preceding Example, the socket includes an outwardly flared end.
According to another example, (“Example 10”), further to any preceding Example, the socket includes a reinforced end.
According to another example, (“Example 11”), further to any preceding Example, the first component is an anchor component and the second component is a tether component.
According to another example, (“Example 12”), further to any preceding Example, the implantable device of any preceding claim, further comprising a third component and fourth component, the socket being configured to receive the third and fourth components to enhance the inter-component interaction between the first and third components of the implantable device.
According to another example, (“Example 13”), further to Example 12, the third component is a tether lock component and the fourth component is a tether component.
According to another example, (“Example 14”), further to any preceding Example, at least one of an outer and an inner surface of the socket includes material configured to promote tissue ingrowth.
According to another example, (“Example 15”), further to any preceding Example, the socket is formed of one or more layers of material including a film microstructure in which fibrillar orientation is in a direction aligned to a longitudinal axis of socket.
According to another example, (“Example 16”), further to any preceding Example, the socket is formed from a material set including ePTFE graft material, elastomer material, other polymeric material, or a combination of two or more such materials.
According to another example, (“Example 17”), further to any preceding Example, the socket includes an ePTFE stretch graft material.
According to another example, (“Example 18”), further to any preceding Example, the socket includes material that is partially or fully bio-resorbable and/or partially or fully bio-absorbable.
According to another example, (“Example 19”), further to any preceding Example, the socket is configured to provide temporary fixation to body tissue that degrades partially or fully over time.
According to another example, (“Example 20”), further to any preceding Example, the socket includes one or more layers configured as a mesh or network of material that is adapted to enhance biocompatibility and fibrosis following implantation.
According to another example, (“Example 21”), further to Example, 20, the mesh or network of material is formed by crossing strands of material or by intermittent voids or openings in one or more layers of material.
According to another example, (“Example 22”), further to any preceding Example, the implantable device is configured as a transcatheter mitral chordal repair device or a blood pump device.
According to another example, (“Example 23”), a method of treatment using the implantable device of any preceding Example includes delivering the implantable device to a location in a body of a patient.
According to another example, (“Example 24”), further to Example 23, the method further includes inserting another component, such as the third component of Example 12, into the socket in vivo.
According to another Example (“Example 25”), an implantable device includes a first component having a first outer profile defining first radial variability along the first component and a socket extending over the first outer profile of the first component to define a second outer profile having a second radial variability that is reduced relative to the first radial variability, wherein the socket includes one or more outer exposed surfaces configured to exhibit one or more tiers of foreign body responses within a range of possible foreign body responses. Any of the features of Examples 1 to 24 may be applicable to Example 25 as appropriate.
According to another Example (“Example 26”), a socket is configured to extend over a first outer profile of a first component of an implantable device to define a second outer profile having a second radial variability that is reduced relative to a first radial variability of the first component, wherein the socket includes one or more outer exposed surfaces configured to exhibit one or more tiers of foreign body responses within a range of possible foreign body responses.
According to another Example (“Example 27”), a socket is configured to extend over a first component and a second component of an implantable device, the socket being configured to enhance the inter-component interaction between the first and second components of the implantable device by reducing relative movement between the first and second components, wherein the socket includes one or more outer exposed surfaces configured to exhibit one or more tiers of foreign body responses within a range of possible foreign body responses.
According to another Example (“Example 28”), a method includes delivering a multi-component device to a location in a body of a patient, the multi-component device including a first component having a first outer profile defining first radial variability along the first component; and a socket extending over the first outer profile of the first component to define a second outer profile having a second radial variability that is reduced relative to the first radial variability, wherein the socket includes one or more outer exposed surfaces configured to exhibit one or more tiers of foreign body responses within a range of possible foreign body responses; and inserting a third component into the socket to enhance the inter-component interaction between the first and third components of the implantable device.
According to another example (“Example 25”), further to the method of Example 24, the third component is a tether lock component.
The foregoing Examples are just that and should not be read to limit or otherwise narrow the scope of any of the inventive concepts otherwise provided by the instant disclosure. While multiple examples are disclosed, still other embodiments will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative examples. Any of a variety of additional or alternative features and advantages are contemplated and will become apparent with reference to the disclosure and figures that follow. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature rather than restrictive in nature.
The accompanying drawings are included to provide a further understanding of the disclosure and are incorporated in and constitute a part of this specification, illustrate embodiments, and together with the description explain the principles of the disclosure.
Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatus configured to perform the intended functions. It should also be noted that the accompanying drawing figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the drawing figures should not be construed as limiting.
This disclosure is not meant to be read in a restrictive manner. For example, the terminology used in the application should be read broadly in the context of the meaning those in the field would attribute such terminology.
The terms “substantially” and “generally” are used in the present disclosure to convey a degree of inexactitude as would be understood and readily ascertainable by a person having ordinary skill in the art.
With respect terminology of inexactitude with reference to measurements, the terms “about” and “approximately” may be used, interchangeably, to refer to a measurement that includes the stated measurement and that also includes any measurements that are reasonably close to the stated measurement. Measurements that are reasonably close to the stated measurement deviate from the stated measurement by a reasonably small amount as understood and readily ascertained by individuals having ordinary skill in the relevant arts. Such deviations may be attributable to measurement error or minor adjustments made to optimize performance, for example. In the event it is determined that individuals having ordinary skill in the relevant arts would not readily ascertain values for such reasonably small differences, the terms “about” and “approximately” can be understood to mean plus or minus 10% of the stated value.
As used herein, the term “tube” does not require a component with a continuous wall unless otherwise noted, but can include meshes, frameworks, perforated constructs, annular or ring constructs, and the like.
As used herein, the term “socket” is inclusive of and may be used interchangeably with any of the following terms: covers, receptacles, shrouds, couplers, constrainers, retaining members and the like.
Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatuses configured to perform the intended functions. It should also be noted that the accompanying drawing figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the drawing figures should not be construed as limiting.
Although the implantable device 10 is subsequently described with reference to components that may be associated with a transcatheter mitral chordal repair device (e.g., such as those disclosed in U.S. Pat. App. Pub. No. 2018/0185151, “METHOD FOR TRANSVASCULAR IMPLANTATION OF NEO CHORDAE TENDINAE,”) similar principles may be applied to any of a variety of implantable devices as desired (see, e.g.,
As shown, in some examples the first component 22 is configured as an anchor component having a body 40 and a barb 42. In some examples, the body component is configured to be delivered endoluminally (e.g., via transcatheter technique) and is formed of a biocompatible metal or polymeric material, for example. The barb 42 may be formed of the same, similar or different material from the body 40 and is configured to be rotated, or screwed into tissue (e.g., cardiac tissue, such as that associated with the ventricular wall of a heart). In turn, the second component 24 may be configured as a tether component formed of a relatively flexible, elongate material (e.g., monofilament, multifilament, braided, or other material). In some examples, the second component is formed of expanded polytetrafluoroethylene (ePTFE), although any of a variety of materials may be used as desired. Although the barb 42 is shown as a helical, screw type anchor, it should be understood that any of a variety of anchoring or engagement features may be substituted for the barb 42 or added in addition to the barb 42. For example, needles, arrow-shaped barbs, expanding coils or umbrella-type anchors, pledget tissue anchors, or any of a variety of other tissue anchor designs are contemplated.
As shown in
As shown in
Additionally or alternatively, as subsequently described, the socket 30 may be adapted to enhance the inter-environment interaction between the first component 22 and the second component 24 and the bodily environment (not shown). For example, the socket 30 may include one or more coatings, layers, surface treatments, or other enhancements configured to promote tissue ingrowth, inhibit tissue ingrowth, reduce thrombosis and combinations thereof in order to promote, or enhance desirable interactions between the implantable device 10 and the bodily environment in which the implantable device 10 is implanted.
As shown in
Some methods include forming a precursor tube 100 that is then formed into the socket 30. Thus, some methods of manufacture include first providing the precursor tube 100. The precursor tube 100 may be formed using wrapping techniques (e.g., tape material that is helically wrapped onto a mandrel to form the precursor tube 100 and/or sheet material that is cigarette wrapped onto a mandrel), extrusion techniques, molding techniques, combinations thereof, or other manufacturing techniques as desired. The precursor tube may be formed as a monolayer or multi-layer construct as desired. The precursor tube 100 may be formed of any of a variety of materials using any of a variety of methods, including any of those previously described. In one example, the precursor tube 100 includes one or more layers of fluoropolymer (e.g., ePTFE) material. The precursor tube 100 may generally be in the form of a hollow right cylinder, may include tapers or steps, or may have any of a variety of additional or alternative features. As shown in
Some methods of forming the socket 30 and coupling the socket 30 to the first component 22 can be understood with reference starting at
As shown in
As shown in
As shown in
The reinforcing rings 304, whether continuous (e.g., continuous helical, undulating pattern) or discontinuous (e.g., discrete, undulating pattern), may be formed of a material that is elastically deformable (e.g., distensible) such that the one or more reinforcing rings 304 will then return to its original diameter when an outer radial force is removed from the reinforcing ring(s) 304. The one or more reinforcing rings 304 can be formed of any suitable material, such as metallic materials (e.g., nitinol or stainless steel) or polymeric materials (e.g., elastomers) as desired.
As shown, an outer portion 306 may then be disposed over the inner portion 202 and the one or more reinforcing rings 304. The outer portion 306 may be wrapped (e.g., tape wrapped), extruded, molded or otherwise formed and may be one layer or a plurality of layers as desired.
In the examples above, the socket 30 is configured with the ability for one or more portions of the socket 30 to be expanded to an expanded diameter and then resiliently recover from such expansion. Although such examples address this feature via incorporation of elastically recoverable stent-like structure(s), the socket 30 may incorporate additional or alternative features to achieve such resilient retraction following diametric expansion. For example, materials of the socket 30 may have elastomeric materials included in one or more layers of material forming the socket 30 such that the socket 30 exhibits the ability to be diametrically distended and then elastically recover. One option includes forming one or more layers of the socket 30 of an elastomeric material (e.g., FEP). Another option would include incorporating an elastomeric material into one or more layers of the socket 30 (e.g., by coating or imbibing an expandable substrate material, such as ePTFE with an elastomeric material).
In terms of assembly and potential advantages of incorporating elastic recovery properties,
The materials implemented for any of the foregoing examples of the socket 30, may be configured to exhibit desired mechanical properties and/or to produce a desired response from the bodily environment. In some examples, the socket 30 includes one or more layer(s) of longitudinally-oriented material for axial, or column strength. For example, the layer(s) may include an expanded fluoropolymer with a microstructure that is oriented to provide longitudinal strength. One such material may include an expanded fluoropolymer (e.g., ePTFE) with a fibril structure that is oriented longitudinally relative to the socket 30 to enhance longitudinal, or column strength of the socket 30. The materials of the socket may also include one or more layer(s) of circumferentially-oriented material for radial, or hoop strength. For example, the socket 30 may include one or more layer(s) of circumferentially-oriented material for radial, or hoop strength. For example, the layer(s) may include an expanded fluoropolymer with a microstructure that is oriented to provide radial or hoop strength. One such material may include an expanded fluoropolymer (e.g., ePTFE) with a fibril structure that is oriented circumferentially relative to the socket 30 to enhance radial or hoop strength of the socket 30. Additionally or alternatively, such layer(s) may be combined, or may include multiple orientations (e.g., both longitudinal and circumferential) in order to achieve desired characteristics.
Additionally or alternatively, the microstructure of one or more interior or exterior layer(s) may be oriented to promote wear and abrasion resistance. For example, where abrasion is likely to be encountered in a longitudinal direction relative to the socket 30, an expanded fluoropolymer such as ePTFE with a fibril microstructure may have the fibrils oriented in the longitudinal direction—i.e., in the direction of wear or abrasion. This may be particularly advantageous in the example of a uniaxially oriented fibril microstructure. Additionally, a relatively more dense (e.g., less porous) microstructure may be employed to enhance overall wear and abrasion resistant of inner or outer layers of the socket 30. Abrasion and wear resistance of the socket 30 may be promoted via other additional or alternative features. For example, an abrasion resistant coating may be applied to an exterior or interior surface of the socket 30. One such coating may be a copolymer of Tetrafluoroethylene (TFE) and Perfluoromethylvinylether (PMVE). As another example of a wear/abrasion resistant coating, a hydrophilic and/or lubricious material may be employed, such as a hydrogel coating. These are just some examples, and other wear resistant features that may be employed in addition to, or as an alternative to abrasion-, or wear-resistant microstructures.
In view of at least the foregoing, various examples include the materials forming the socket 30 promoting tissue ingrowth (e.g., to reduce thrombosis or help secure the multicomponent implantable device 10 at a desired implant location). Additionally, in some implementations, materials forming the socket 30 include a film microstructure in which fibrillar orientation is in a direction substantially parallel the longitudinal axis of socket 30. Such a configuration can help ensure that longitudinal motion of one or more or each of the plurality of components 20 (e.g., anchor components, tether components, and/or tether lock components) will be aligned with the fibrillar orientation to help reduce friction and/or wear on the component(s).
In various examples, the socket 30 may be formed from a material set including ePTFE graft material, elastomer material, other polymeric material, or combinations of such materials. In some embodiments, the socket 30 is constructed from ePTFE stretch graft material, such as material similar to that available from W.L. Gore & Associates, Inc. under the trade name “GORE-TEX” brand “Stretch Vascular Grafts.” The socket 30 may include material modified to enhance column strength (e.g., by including one or more layers of material that are relatively denser, or less porous). The socket 30 may also include materials that are partially or fully bio-resorbable or bio-absorbable. In such examples, the socket 30 can be configured to provide temporary fixation (e.g., between component(s) and or with the body) which degrades partially or fully over time.
In some embodiments, the socket 30 includes one or more layers configured as a mesh, or network of material, that is adapted to enhance biocompatibility and fibrosis following implantation. Such mesh or network may be formed by crossing strands of material, or by forming intermittent voids or openings in a layer of material. Such mesh or network configurations may be implemented to promote tissue growth onto and/or through the mesh or network surface. In some examples, tissue growth may be promoted by incorporating a relatively rough and/or porous outer and/or inner surface into the socket 30. If desired, one or more holes may be formed into or through the socket material, which may promote the formation of scar tissue fibrocytes (e.g., to promote strong fixation to tissue).
It should be understood that the other component(s) of the implantable device 10 may employ similar features to enhance wear or abrasion resistance of those components. For example, as previously referenced, the second component 24 may be configured as a tether component formed of a relatively flexible, elongate material (e.g., monofilament, multifilament, braided, or other material). Where abrasion is likely to be encountered in a longitudinal direction relative to the socket 30, an expanded fluoropolymer such as ePTFE with a fibril microstructure may have the fibrils oriented in the longitudinal direction—i.e., in the direction of wear or abrasion. Again, this may be particularly advantageous in the example of a uniaxially oriented fibril microstructure. Again, a relatively more dense (e.g., less porous) microstructure may be employed (e.g., a relatively more dense ePTFE or expanded (fluoro)polymer) to enhance overall wear and abrasion resistant of the second component 24.
Similarly to the socket 30, abrasion and wear resistance may also be promoted via other additional or alternative features. For example, an abrasion resistant coating may be applied to the second component 24. One such coating may be a copolymer of Tetrafluoroethylene (TFE) and Perfluoromethylvinylether (PMVE). As another example of a wear/abrasion resistant coating, a hydrophilic and/or lubricious material may be employed, such as a hydrogel coating. Again, these are just some examples, and other wear resistant features that may be employed in addition to, or as an alternative to abrasion-, or wear-resistant microstructures. It should also be understood that similar principals may be applied to the other components of the implantable device 10, such as the fourth component 28.
In some examples, one or more layer(s) of the socket 30 may be formed of a material having a desired permeability. For example, in some examples the socket includes one or more layers that are impermeable to cellular integration, or which are impermeable to body fluids such as blood or blood serum, to improve overall mechanical characteristics and/or biologic response as desired.
In some examples, the outermost layer(s) may have an internodal distance or spacing of greater than or equal to 6 micrometers.
In some examples, the outermost layer(s), or exposed surface layer(s), may be configured to achieve one or more tiers within a range of biologic, or foreign body responses.
A first tier of foreign body responses (e.g., at a first relative material porosity) would include impermeability to blood plasma and serum.
A second tier of foreign body responses (e.g., at a second relative material porosity) would include plasma and/or serum infiltration into the exposed surface.
A third tier of foreign body responses (e.g., at a third, higher relative material porosity) would include minimal, or some level of extracellular matrix integration.
A fourth tier of foreign body response (e.g., at a fourth, even higher relative material porosity) would include cellular integration.
A fifth tier of foreign body responses (e.g., at a fifth, highest relative material porosity) would include vascular integration, including full tissue ingrowth and blood vessels supplying the tissue. The outermost, or exposed surface(s) can be tailored to exhibit any of these relative tiers of foreign body responses as desired, for example by selecting material microstructure, coatings, and/or surface treatments.
An assessment of whether or not the material is exhibiting a particular tier of foreign body response may be made using a variety of techniques. Measurement techniques for assessing the presence of one or more tiers of foreign body response could include a permeability test such as those described according to ASTM standards. In various examples, a histology assessment may be an appropriate tool for assessing foreign body responses under any of the various tiers previously described.
The foreign body response of the outermost layer or surface may be additionally or alternatively tailored through the use of coatings and/or surface treatments. For example, the outermost layer(s) may be treated with heparin bonding (e.g., including that sold under the tradename “CBAS” by W.L. Gore & Associates, Inc. and Carmeda AB, which is a heparin bonding technology for lasting thromboresistance). As another example, the socket 30 may be tailored to include one or more eluting technologies, such as drug elution technologies. Any of a variety of biological coatings can be included on the outer and/or inner surfaces of the socket 30 to achieve a desired biologic response, including promoting healing and/or tissue growth, for example.
As previously referenced, the socket 30 and any of the foregoing features and examples thereof may be applied in a variety of device contexts. For example,
The implantable device 410 in the example of
Various methods of treatment using the implantable devices of any of the preceding examples include delivering the implantable device to a location in a body of a patient (e.g., into a heart of a patient). In various examples, another component (e.g., the third component 26) is received in the socket 30 in vivo (e.g., by being slid into the socket 30 as part of a tensioning or other process in association with a transcatheter mitral chordal repair method).
Although the various examples above are cast in the context of an implantable device, the various concepts and features above may also be applied in the context of a single component as desired. For the avoidance of doubt, the scope of invention is not limited to multi-component implantable devices. Specifically, in some examples, the socket 30 may be implemented in association with a single component, and need not be configured to and/or actually receive any additional, discrete components. For example, the socket 30 can be used to help smooth, or reduce radial profile variability. Transverse elements of the component that protrude relative to a surrounding portion of the outer profile could result in thrombosis, or damage to surrounding tissue, for example.
Inventive concepts of this application have been described above both generically and with regard to specific embodiments/examples. It will be apparent to those skilled in the art that various modifications and variations can be made in the embodiments without departing from the scope of the disclosure. Thus, it is intended that the embodiments cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.
This application claims the benefit of Provisional Application No. 62/778,654, filed Dec. 12, 2018, which is incorporated herein by reference in its entirety for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
3618604 | Ness | Nov 1971 | A |
3683928 | Kuntz | Aug 1972 | A |
3828777 | Ness | Aug 1974 | A |
3960150 | Hussain et al. | Jun 1976 | A |
3962414 | Michaels | Jun 1976 | A |
4014335 | Arnold | Mar 1977 | A |
4182342 | Smith | Jan 1980 | A |
4579221 | Corella | Apr 1986 | A |
4759759 | Walker et al. | Jul 1988 | A |
5037434 | Lane | Aug 1991 | A |
5147647 | Darougar | Sep 1992 | A |
5163955 | Love et al. | Nov 1992 | A |
5282851 | Jacob-LaBarre | Feb 1994 | A |
5378475 | Smith et al. | Jan 1995 | A |
5423777 | Tajiri et al. | Jun 1995 | A |
5681275 | Ahmed | Oct 1997 | A |
5702414 | Richter et al. | Dec 1997 | A |
5708044 | Branca | Jan 1998 | A |
5713953 | Vallana et al. | Feb 1998 | A |
5773019 | Ashton et al. | Jun 1998 | A |
5861028 | Angell | Jan 1999 | A |
5882327 | Jacob | Mar 1999 | A |
5928281 | Huynh et al. | Jul 1999 | A |
5935163 | Gabbay | Aug 1999 | A |
6074419 | Healy et al. | Jun 2000 | A |
6086612 | Jansen | Jul 2000 | A |
6142969 | Nigam | Nov 2000 | A |
6171335 | Wheatley et al. | Jan 2001 | B1 |
6174331 | Moe et al. | Jan 2001 | B1 |
6197143 | Bodnar | Mar 2001 | B1 |
6254636 | Peredo | Jul 2001 | B1 |
6283995 | Moe et al. | Sep 2001 | B1 |
6287338 | Sarnowski et al. | Sep 2001 | B1 |
6364905 | Simpson et al. | Apr 2002 | B1 |
6432542 | Tsai | Aug 2002 | B1 |
6450984 | Lynch et al. | Sep 2002 | B1 |
6471689 | Joseph et al. | Oct 2002 | B1 |
6541589 | Baillie | Apr 2003 | B1 |
6562069 | Cai et al. | May 2003 | B2 |
6613086 | Moe et al. | Sep 2003 | B1 |
6613087 | Healy et al. | Sep 2003 | B1 |
6696526 | Kaulbach et al. | Feb 2004 | B1 |
6699210 | Williams et al. | Mar 2004 | B2 |
6699211 | Savage | Mar 2004 | B2 |
6713081 | Robinson et al. | Mar 2004 | B2 |
6994666 | Shannon et al. | Feb 2006 | B2 |
7018404 | Holmberg et al. | Mar 2006 | B2 |
7261732 | Justino | Aug 2007 | B2 |
7306729 | Bacino et al. | Dec 2007 | B2 |
7320705 | Quintessenza | Jan 2008 | B2 |
7331993 | White | Feb 2008 | B2 |
7361189 | Case et al. | Apr 2008 | B2 |
7462675 | Chang et al. | Dec 2008 | B2 |
7531611 | Sabol et al. | May 2009 | B2 |
7604663 | Reimink et al. | Oct 2009 | B1 |
7833565 | O'Connor et al. | Nov 2010 | B2 |
7862610 | Quintessenza | Jan 2011 | B2 |
8216631 | O'Connor et al. | Jul 2012 | B2 |
8219229 | Cao et al. | Jul 2012 | B2 |
8246676 | Acosta et al. | Aug 2012 | B2 |
8267994 | Jin | Sep 2012 | B2 |
8273101 | Garcia et al. | Sep 2012 | B2 |
8303647 | Case | Nov 2012 | B2 |
8399006 | De Juan, Jr. et al. | Mar 2013 | B2 |
8545430 | Silvestrini | Oct 2013 | B2 |
8556960 | Agnew et al. | Oct 2013 | B2 |
8623395 | De et al. | Jan 2014 | B2 |
8632489 | Ahmed | Jan 2014 | B1 |
8637144 | Ford | Jan 2014 | B2 |
8690939 | Miller | Apr 2014 | B2 |
8834406 | Snyder et al. | Sep 2014 | B2 |
8834911 | Glezer et al. | Sep 2014 | B2 |
8961593 | Bonhoeffer et al. | Feb 2015 | B2 |
8961599 | Bruchman et al. | Feb 2015 | B2 |
8961600 | Nissan et al. | Feb 2015 | B2 |
9139669 | Xu et al. | Sep 2015 | B2 |
9155610 | Soletti et al. | Oct 2015 | B2 |
9155618 | Kalmann et al. | Oct 2015 | B2 |
9259313 | Wheatley | Feb 2016 | B2 |
9301835 | Campbell et al. | Apr 2016 | B2 |
9301837 | Beith | Apr 2016 | B2 |
9326891 | Horvath et al. | May 2016 | B2 |
9364322 | Conklin et al. | Jun 2016 | B2 |
9370444 | Cunningham, Jr. | Jun 2016 | B2 |
9539089 | Beith | Jan 2017 | B2 |
9572713 | Lind et al. | Feb 2017 | B2 |
9636219 | Keidar et al. | May 2017 | B2 |
9636254 | Yu et al. | May 2017 | B2 |
9655720 | Bluestein et al. | May 2017 | B2 |
9675453 | Guttenberg et al. | Jun 2017 | B2 |
9833314 | Corbett | Dec 2017 | B2 |
9849629 | Zagl et al. | Dec 2017 | B2 |
9987120 | Soletti et al. | Jun 2018 | B2 |
9999500 | Greenslet et al. | Jun 2018 | B2 |
10052200 | Chung et al. | Aug 2018 | B2 |
10195023 | Wrobel | Feb 2019 | B2 |
10299915 | Edelman et al. | May 2019 | B2 |
10307292 | Litvin | Jun 2019 | B2 |
10413402 | Squara | Sep 2019 | B2 |
10413403 | Boden et al. | Sep 2019 | B2 |
10426609 | Edelman et al. | Oct 2019 | B2 |
10433955 | Edelman et al. | Oct 2019 | B2 |
10512537 | Corbett et al. | Dec 2019 | B2 |
10588746 | Bernstein et al. | Mar 2020 | B2 |
10603164 | Girard et al. | Mar 2020 | B2 |
11351058 | Roeber et al. | Jun 2022 | B2 |
20020106395 | Brubaker | Aug 2002 | A1 |
20020110635 | Brubaker et al. | Aug 2002 | A1 |
20020156413 | Williams et al. | Oct 2002 | A1 |
20020198594 | Schreck | Dec 2002 | A1 |
20030027332 | Lafrance et al. | Feb 2003 | A1 |
20030088260 | Smedley et al. | May 2003 | A1 |
20030094731 | Simpson | May 2003 | A1 |
20030109923 | Chinn et al. | Jun 2003 | A1 |
20040024345 | Gharib et al. | Feb 2004 | A1 |
20040215333 | Duran et al. | Oct 2004 | A1 |
20050085892 | Goto et al. | Apr 2005 | A1 |
20050137538 | Kunzler et al. | Jun 2005 | A1 |
20050171507 | Christian et al. | Aug 2005 | A1 |
20050182350 | Nigam | Aug 2005 | A1 |
20050228487 | Kujawski | Oct 2005 | A1 |
20050234546 | Nugent et al. | Oct 2005 | A1 |
20050261759 | Lambrecht et al. | Nov 2005 | A1 |
20050266047 | Tu et al. | Dec 2005 | A1 |
20050273033 | Grahn et al. | Dec 2005 | A1 |
20060109923 | Cai et al. | May 2006 | A1 |
20060110429 | Reiff et al. | May 2006 | A1 |
20060189917 | Mayr et al. | Aug 2006 | A1 |
20060195187 | Stegmann et al. | Aug 2006 | A1 |
20060258994 | Avery | Nov 2006 | A1 |
20070078371 | Brown et al. | Apr 2007 | A1 |
20070083184 | Simpson | Apr 2007 | A1 |
20070088432 | Solovay et al. | Apr 2007 | A1 |
20070118147 | Smedley et al. | May 2007 | A1 |
20070293872 | Peyman | Dec 2007 | A1 |
20080071361 | Tuval et al. | Mar 2008 | A1 |
20080082161 | Woo | Apr 2008 | A1 |
20080091261 | Long et al. | Apr 2008 | A1 |
20080133005 | Andrieu et al. | Jun 2008 | A1 |
20080200977 | Paul et al. | Aug 2008 | A1 |
20080264993 | Schulte et al. | Oct 2008 | A1 |
20080312737 | Jin | Dec 2008 | A1 |
20090157175 | Benichou | Jun 2009 | A1 |
20090240320 | Tuval et al. | Sep 2009 | A1 |
20090299469 | Kollar | Dec 2009 | A1 |
20100015200 | Mcclain et al. | Jan 2010 | A1 |
20100082094 | Quadri et al. | Apr 2010 | A1 |
20100114307 | Agnew et al. | May 2010 | A1 |
20100114309 | De et al. | May 2010 | A1 |
20100119580 | Guo et al. | May 2010 | A1 |
20100137981 | Silvestrini et al. | Jun 2010 | A1 |
20100161040 | Braido et al. | Jun 2010 | A1 |
20100168644 | Brown | Jul 2010 | A1 |
20100168839 | Braido et al. | Jul 2010 | A1 |
20100185277 | Braido et al. | Jul 2010 | A1 |
20100241046 | Pinchuk et al. | Sep 2010 | A1 |
20110112620 | Du | May 2011 | A1 |
20110196487 | Badawi et al. | Aug 2011 | A1 |
20110244014 | Williams et al. | Oct 2011 | A1 |
20110257738 | Corbei, I et al. | Oct 2011 | A1 |
20110270388 | Stevens | Nov 2011 | A9 |
20110276128 | Cao et al. | Nov 2011 | A1 |
20110282440 | Cao et al. | Nov 2011 | A1 |
20110288635 | Miller et al. | Nov 2011 | A1 |
20120035525 | Silvestrini | Feb 2012 | A1 |
20120123315 | Horvath et al. | May 2012 | A1 |
20120123317 | Horvath et al. | May 2012 | A1 |
20120165720 | Horvath et al. | Jun 2012 | A1 |
20120197175 | Horvath et al. | Aug 2012 | A1 |
20120253453 | Bruchman et al. | Oct 2012 | A1 |
20120310137 | Silvestrini | Dec 2012 | A1 |
20120323315 | Bruchman et al. | Dec 2012 | A1 |
20130046379 | Paolitto et al. | Feb 2013 | A1 |
20130211314 | Venkatraman et al. | Aug 2013 | A1 |
20130218081 | Roth | Aug 2013 | A1 |
20130274691 | Dejuan, Jr. et al. | Oct 2013 | A1 |
20130325024 | Nissan et al. | Dec 2013 | A1 |
20130325111 | Campbell et al. | Dec 2013 | A1 |
20140012371 | Li | Jan 2014 | A1 |
20140031927 | Bruchman et al. | Jan 2014 | A1 |
20140128960 | Greenslet et al. | May 2014 | A1 |
20140154321 | Ashton | Jun 2014 | A1 |
20140170204 | Desai et al. | Jun 2014 | A1 |
20140186420 | Utkhede et al. | Jul 2014 | A1 |
20140214158 | Board et al. | Jul 2014 | A1 |
20140236067 | Horvath et al. | Aug 2014 | A1 |
20140236068 | Van et al. | Aug 2014 | A1 |
20140358224 | Tegels | Dec 2014 | A1 |
20150005689 | Horvath et al. | Jan 2015 | A1 |
20150119980 | Beith et al. | Apr 2015 | A1 |
20150224200 | Dejuan, Jr. et al. | Aug 2015 | A1 |
20150224231 | Bruchman et al. | Aug 2015 | A1 |
20150320975 | Simpson et al. | Nov 2015 | A1 |
20150374545 | Horvath et al. | Dec 2015 | A1 |
20160015516 | Bernstein et al. | Jan 2016 | A1 |
20160038412 | Guo et al. | Feb 2016 | A1 |
20160058616 | Camras et al. | Mar 2016 | A1 |
20160067032 | Soletti et al. | Mar 2016 | A1 |
20160100939 | Armstrong et al. | Apr 2016 | A1 |
20160153591 | Fonfara et al. | Jun 2016 | A1 |
20160245432 | Fonfara et al. | Aug 2016 | A1 |
20160256321 | Horvath et al. | Sep 2016 | A1 |
20160256382 | Shi et al. | Sep 2016 | A1 |
20160287513 | Rakic et al. | Oct 2016 | A1 |
20160296322 | Edelman et al. | Oct 2016 | A1 |
20160302965 | Erickson et al. | Oct 2016 | A1 |
20160302967 | Ahn | Oct 2016 | A1 |
20160331528 | Parker et al. | Nov 2016 | A1 |
20160374856 | Pinchuk et al. | Dec 2016 | A1 |
20170000610 | Eppihimer et al. | Jan 2017 | A1 |
20170014227 | Boden et al. | Jan 2017 | A1 |
20170071729 | Wrobel | Mar 2017 | A1 |
20170079779 | Tabor | Mar 2017 | A1 |
20170079782 | Beith | Mar 2017 | A1 |
20170156854 | Hammer | Jun 2017 | A1 |
20170172794 | Varner et al. | Jun 2017 | A1 |
20170189175 | Justino et al. | Jul 2017 | A1 |
20170245989 | Bluestein et al. | Aug 2017 | A1 |
20170252156 | Bernstein et al. | Sep 2017 | A1 |
20170296783 | Connolly et al. | Oct 2017 | A1 |
20170367888 | Brown | Dec 2017 | A1 |
20180049872 | Bennett | Feb 2018 | A1 |
20180125632 | Cully et al. | May 2018 | A1 |
20180133002 | Yi et al. | May 2018 | A1 |
20180177592 | Benichou et al. | Jun 2018 | A1 |
20180185151 | Bishop | Jul 2018 | A1 |
20180263775 | Shah | Sep 2018 | A1 |
20180263817 | Roeber et al. | Sep 2018 | A1 |
20180263818 | Roeber et al. | Sep 2018 | A1 |
20180263819 | Roeber et al. | Sep 2018 | A1 |
20180344457 | Gross et al. | Dec 2018 | A1 |
20190015191 | Berdajs | Jan 2019 | A1 |
20190091014 | Arcaro et al. | Mar 2019 | A1 |
20190091015 | Dienno et al. | Mar 2019 | A1 |
20190125529 | Colavito et al. | May 2019 | A1 |
20190125530 | Arcaro et al. | May 2019 | A1 |
20190125531 | Bennett et al. | May 2019 | A1 |
20190282360 | Colavito et al. | Sep 2019 | A1 |
20190343617 | Sobrino-Serrano et al. | Nov 2019 | A1 |
20190365531 | Beith | Dec 2019 | A1 |
20200113681 | Armstrong et al. | Apr 2020 | A1 |
20200121454 | Spence | Apr 2020 | A1 |
20200188114 | Radspinner et al. | Jun 2020 | A1 |
20210322217 | Roeber et al. | Oct 2021 | A1 |
20210346197 | Roeber et al. | Nov 2021 | A1 |
Number | Date | Country |
---|---|---|
0660012 | Jun 1995 | AU |
2502761 | Apr 1997 | CA |
1208602 | Feb 1999 | CN |
2414757 | Jan 2001 | CN |
1285724 | Feb 2001 | CN |
101965211 | Feb 2011 | CN |
202619978 | Dec 2012 | CN |
103179927 | Jun 2013 | CN |
105579001 | May 2016 | CN |
205198254 | May 2016 | CN |
2349147 | Mar 2015 | EP |
2958530 | Dec 2015 | EP |
2513194 | Oct 2014 | GB |
08-117267 | May 1996 | JP |
11-505159 | May 1999 | JP |
2000-513248 | Oct 2000 | JP |
2002-521145 | Jul 2002 | JP |
2003-301948 | Oct 2003 | JP |
2005-500101 | Jan 2005 | JP |
2007-521125 | Aug 2007 | JP |
2010-540079 | Dec 2010 | JP |
2012-504031 | Feb 2012 | JP |
2013-009982 | Jan 2013 | JP |
2014-517720 | Jul 2014 | JP |
2016-137278 | Aug 2016 | JP |
2001066037 | Sep 2001 | WO |
2003007795 | Jan 2003 | WO |
2005076973 | Aug 2005 | WO |
2007100408 | Sep 2007 | WO |
2008030951 | Mar 2008 | WO |
2008133852 | Nov 2008 | WO |
2009042196 | Apr 2009 | WO |
2009137785 | Nov 2009 | WO |
2010037141 | Apr 2010 | WO |
2011147849 | Dec 2011 | WO |
2012018779 | Feb 2012 | WO |
2012135603 | Oct 2012 | WO |
2013090006 | Jun 2013 | WO |
2013096854 | Aug 2013 | WO |
2014028725 | Feb 2014 | WO |
2014130574 | Aug 2014 | WO |
2014145811 | Sep 2014 | WO |
2015065646 | May 2015 | WO |
2016033270 | Mar 2016 | WO |
2016168686 | Oct 2016 | WO |
2016196841 | Dec 2016 | WO |
2018150392 | Aug 2018 | WO |
2018170429 | Sep 2018 | WO |
2018170433 | Sep 2018 | WO |
2018187714 | Oct 2018 | WO |
2019154927 | Aug 2019 | WO |
Entry |
---|
Ando et al., Ten-year experience with handmade trileaflet polytelianuoroethylene valved conduit used for pulmonary Yeconstruction. The Journal of Thoracic and Cardiovascular Surgery, Jan. 2009, vol. 137, No. 1, pp. 124-131. |
Gedde et al., “Treatment Outcomes in the Tube Versus Trabeculectomy (TVT) Study After Five Years of Follow-up”, Am J Ophthalmol., vol. 153, No. 5, 2012, pp. 789-803. |
Han, et al. “Membrane-tube-type glaucoma shunt device for refractory glaucoma surgery”, Glaucoma, Graefes Arch Clin Exp Opthalmol, DOI 10, 1007/s00417-016-3510-z. Springer-Verlag Berlin Heidelberg 2016. |
International Preliminary Reporton Patentability received for PCT Patent Application No. PCT/US2015/055348, dated Apr. 27, 2017, 18 pages. |
International Preliminary Reporton Patentability received for PCT Patent Application No. PCT/US2018/022922, dated Sep. 26, 2019, 9 pages. |
International Preliminary Reporton Patentability received for PCT Patent Application No. PCT/US2018/022929, dated Sep. 26, 2019, 9 pages. |
International Preliminary Reporton Patentability received for PCT Patent Application No. PCT/US2018/022933, dated Sep. 26, 2019, 9 pages. |
International Preliminary Reporton Patentability received for PCT Patent Application No. PCT/US2019/048759, dated Mar. 11, 2021, 12 pages. |
International Preliminary Reporton Patentability received for PCT Patent Application No. PCT/US2019/048760, dated Mar. 11, 2021, 9 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/055348, dated Apr. 11, 2016, 23 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2018/050771, dated Feb. 25, 2019, 16 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/048759, dated Feb. 12, 2020, 16 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/048760, dated Dec. 3, 2019, 15 pages. |
International Search Report dated Jul. 23, 2018 for PCT/US2018/022922. |
International Search Report of PCT/2018/022933 dated Jul. 3, 2018. |
International Search Report of PCT/US2018/022929 dated Jun. 28, 2018. |
International Search Reportand Written Opinion for PCT/US2015/055348 dated Apr. 11, 2016, corresponding to U.S. Appl. No. 14/881,124, 6 pages. |
Invitation to Pay Additional Fees received for PCT Patent Application No. PCT/US2019/048759, mailed on Dec. 11, 2019, 10 pages. |
Karthikeyan et al., “The concept of ocular inserts as drug delivery systems: An overview”, Asian Journal Of Pharmaceutics, vol. 2, No. 4, 2008, pp. 192-200. |
Lee et al., “Aqueous-Venous Shunt for Glaucoma A Further Report”, Arch Opthalmol, vol. 99, 1981, pp. 2007-2012. |
Lee et al., “Aqueous-Venous Shunt in The Rabbit Eye: A Long-Term Follow-Up”, Trans. Soc. OphthaL Sin., vol. 8, 1969, pp. 7-24. |
Lee et al., “Aqueous-Venus Shunt for Glaucoma: Report on 15 cases”, AnnalOphthal, Oct. 1974, pp. 1083-1088. |
Lee et al., “Effect of an Aqueous-Venous Shunt In The Monkey Eye”, Canad. J. Ophthal., 3:22, 1968, pp. 22-27. |
Lee et al., “Effect of aqueous-venous shunt on rabbit eyes”, Inivestigative Ophthalmology, vol. 5, No. 3, 1996, pp. 304-311. |
Lee et al., “Glaucoma Microsurgery Aqueous-Venous Shunt Procedure”, International Surgery, vol. 57, No. 1, Jan. 1972, pp. 37-41. |
Miyazaki, et al., Expanded polytetrafluoroethylene conduits and patches with bulging sinuses and fan-shaped valves in right ventricular outflow tract reconstruction: Multicneter study in Japan. The Journal of Thoracic and Cardiovascular Surgery, Nov. 2011, vol. 142, No. 5, pp. 1122-1129. |
Miyazaki, et al., Expanded polytetrafluoroethylene valved conduit and patch with bulging sinuses in right ventricular outflow tract reconstruction. The Journal of Thoracic and Cardiovascular Surgery, Aug. 2007, vol. 134, No. 2, pp. 327-332. |
Ootaki et al., Medium-term outcomes after implantation of expanded polytetrafluoroethylene valved conduit. The Annals of Thoracic Surgery, 2018; 105 (3), pp. 843-850. |
Rese et al., “Sustained drug delivery in glaucoma”, Current Opinion in Ophthalmology, vol. 25, No. 2, 2014, pp. 112-117. |
Shinkawa et al., Valved polytetrafluoroethylene conduits for right ventricular outflow tract reconstruction. The Annals of Thoracic Surgery Jul. 2015; 100(1), pp. 129-137. |
Stevenson et al., “Reservoir-Based Drug Delivery Systems Utilizing Microtechnology” Advanced Drug Delivery Reviews, vol. 64, No. 14, 2012, pp. 1590-1602. |
Understanding Your Heart Valve. Medtronic USA, Inc., 2006. Pamphlet. |
Yamagishi et al. Outflow reconstruction of tetralogy of fallot using a Gore-Tex valve. The Anais of Thoracic Surgery, Dec. 1993; 56(6), pp. 1414-1417. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/065890, dated Mar. 18, 2020, 9 pages. |
International Preliminary Reporton Patentability received for PCT Patent Application No. PCT/US2019/065890, dated Jun. 24, 2021, 8 pages. |
Number | Date | Country | |
---|---|---|---|
20200188114 A1 | Jun 2020 | US |
Number | Date | Country | |
---|---|---|---|
62778654 | Dec 2018 | US |